Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 1014 years

Journal of Adolescent Health

Volumn 50, Issue 2, 2012, Pages 187-194

  Schwarz, Tino F ^a   Huang, Li Min ^b   Medina, Doris Maribel Rivera ^c   Valencia, Alejandra ^d   Lin, Tzou Yien ^e   Behre, Ulrich ^f   Catteau, Grgory ^g   Thomas, Florence ^g   Descamps, Dominique ^g  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c Organizacin Para El Desarrollo y la Investigacin Salud en Honduras   (Honduras)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^e CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^f Pediatric Practice Kehl   (Germany)

^g GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adolescent; Cervical cancer; Female; HPV 16 18 AS04 adjuvanted vaccine; Human papillomavirus; Immunogenicity; Long term; Monophosphoryl lipid A; Safety

Indexed keywords

PHOSPHORYL LIPID A; VIRUS ANTIBODY; WART VIRUS VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALLERGIC RHINITIS; ANTIBODY TITER; APPENDICITIS; ARTICLE; ASTHMA; BRONCHITIS; CHILD; COLOMBIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTRITIS; GERMANY; HONDURAS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HYPERSENSITIVITY; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MIGRAINE; OVARY CYST; PANAMA; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TAIWAN; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOGENETIC PROCESSES; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84856090807     PISSN: 1054139X     EISSN: 18791972     Source Type: Journal    
DOI: 10.1016/j.jadohealth.2011.11.004     Document Type: Article

References (29)

1. J.M. Walboomers, M.V. Jacobs, M.M. Manos Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J Pathol 189 1999 12 19 (Pubitemid 29406813)
2. J. Ferlay, H.R. Shin, F. Bray GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide IARC CancerBase No. 10 2010 International Agency for Research on Cancer Lyon, France http://globocan.iarc.fr Accessed September 9, 2010
3. F.X. Bosch, A.N. Burchell, M. Schiffman Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia Vaccine 26S 2008 K1 K6
4. S. Collins, S. Mazloomzadeh, H. Winter High incidence of cervical human papillomavirus infection in women during their first sexual relationship Br J Obstet Gynaecol 109 2002 96 98
5. A.B. Moscicki HPV infections in adolescents Dis Markers 23 2007 229 234
6. D.R. Brown, M.L. Shew, B. Qadadri A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women J Infect Dis 191 2005 182 192 (Pubitemid 40096375)
7. K. Wellings, M. Collumbien, E. Slaymaker Sexual behaviour in context: A global perspective Lancet 368 2006 1706 1728 (Pubitemid 46055217)
8. T.C. Wright, W.K. Huh, B.J. Monk Age considerations when vaccinating against HPV Gynecol Oncol 109 2008 S40 S47
9. J. Tripp, R. Viner ABC of adolescence Sexual health, contraception and teenage pregnancy BMJ 330 2005 590 593 (Pubitemid 40380356)
10. L.G. Whalen, J.A. Grunbaum, S. Kinchen Middle School: Youth Risk Behavior Survey 2003 2005 US Department of Health and Human Services, Centers for Disease Control and Prevention Atlanta, GA
11. S. Franceschi, R. Herrero, G.M. Clifford Variations in the age-specific curves of human papillomavirus prevalence in women worldwide Int J Cancer 119 2006 2677 2684 (Pubitemid 44691325)
12. D.M. Harper, E.L. Franco, C.M. Wheeler Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial Lancet 364 2004 1757 1765 (Pubitemid 39488060)
13. D.M. Harper, E.L. Franco, C.M. Wheeler Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial Lancet 367 2006 1247 1255
14. The GlaxoSmithKline Vaccine HPV-007 Study Group Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years Lancet 374 2009 1975 1985
15. J. Paavonen, D. Jenkins, F.X. Bosch Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial Lancet 369 2007 2161 2170 (Pubitemid 46977438)
16. J. Paavonen, P. Naud, J. Salmern Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types PATRICIA: Final analysis of a double-blind, randomised study in young women Lancet 374 2009 301 314
17. ® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 1845 years Hum Vaccin 5 2009 705 719
18. Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from months 1224 in a phase III randomized study of healthy women aged 1845 years. Hum Vaccin (in press).
19. M. Lehtinen, J. Paavonen, C.M. Wheeler HPV PATRICIA Study Group Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Lancet Oncol 2011 Nov 8 10.1016/S1470-2045(11)70286-8 [Epub ahead of print]
20. D. Descamps, K. Hardt, B. Spiessens Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials Hum Vaccin 5 2009 332 340
21. T. Verstraeten, D. Descamps, M.P. David Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines Vaccine 26 2008 6630 6638
22. C. Pedersen, T. Petaja, G. Strauss Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant J Adolesc Health 40 2007 564 571 (Pubitemid 46771257)
23. T. Petj, C. Pedersen, A. Poder Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women Int J Cancer 129 2011 2147 2157
24. S.L. Giannini, E. Hanon, P. Moris Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only Vaccine 24 2006 5937 5949 (Pubitemid 44080367)
25. N. Garon, P. Chomez, M. van Mechelen GlaxoSmithKline Adjuvant Systems in vaccines: Concepts, achievements and perspectives Expert Rev Vaccines 6 2007 723 739 (Pubitemid 47607848)
26. N. Garon Preclinical development of AS04 Methods Mol Biol 626 2010 15 27
27. B. Beutler, E.T. Rietschel Innate immune sensing and its roots: The story of endotoxin Nat Rev Immunol 3 2003 169 176 (Pubitemid 37328694)
28. D.M. Medina, A. Valencia, A. de Velasquez Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: A randomized, controlled trial in adolescent girls J Adolesc Health 46 2010 414 421
29. M.P. David, K. Van Herck, K. Hardt Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses Gynecol Oncol 115 suppl 3 2009 S1 S6